검색
Neumora Therapeutics Inc
NMRA관심 목록에 추가
1.670USD
+0.050+3.09%
종가 07/02, 13:00（ET）시세는 15분 지연됩니다
304.20M시가총액
손실P/E TTM
자세한 내용은 Neumora Therapeutics Inc 회사
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
Neumora Therapeutics Inc 정보
종목 코드 NMRA
회사 이름Neumora Therapeutics Inc
상장일Sep 15, 2023
CEOBerns (Paul L)
직원 수110
유형Ordinary Share
회계 연도 종료Sep 15
주소260 Arsenal Place, Suite 1
도시WATERTOWN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호02472
전화18577600900
웹사이트https://neumoratx.com/
종목 코드 NMRA
상장일Sep 15, 2023
CEOBerns (Paul L)
Neumora Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.71M
+0.56%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
--
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
34.02K
-265.51%
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
21.03K
-6.83%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
20.10K
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
Mr. Alaa A. Halawa
Mr. Alaa A. Halawa
Independent Director
Independent Director
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. David Piacquad
Mr. David Piacquad
Independent Director
Independent Director
--
--
Ms. Helen Rubinstein
Ms. Helen Rubinstein
IR Contact Officer
IR Contact Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.71M
+0.56%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
--
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
34.02K
-265.51%
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
21.03K
-6.83%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
20.10K
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
자주 묻는 질문
Neumora Therapeutics Inc의 상위 5대 주주는 누구인가요?
Neumora Therapeutics Inc의 상위 5대 주주는 다음과 같습니다: Mr. Paul L. Berns
Neumora Therapeutics Inc(NMRA)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Neumora Therapeutics Inc의 주식을 보유한 기관은 총 301곳이며, 이들이 보유한 주식의 총 가치는 약 106.55M로 전체 발행 주식의 57.52%를 차지합니다. 이는 2025Q4 대비 -16535931.00 증가한 수치입니다.